What to watch: USFDA nod for asthma drug may boost Lupin

| Updated on November 08, 2019 Published on November 09, 2019

Lupin on Friday said it has received approval from the US Food and Drug Administration for its generic Zileuton extended-release tablets used as prophylaxis and in treatment of chronic asthma in adults and children 12 years of age and older. Citing IQVIA MAT September 2019 data, the company said Zileuton extended-release tablets (600 mg) had annual sales of approximately $43 million in the US. Shareholders will closely monitor product launch and further development.

Published on November 09, 2019
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.